Related Experiment Video
Updated: Dec 9, 2025
09:22
Ultrafast Lignin Extraction from Unusual Mediterranean Lignocellulosic Residues
Published on: March 9, 2021
7.3K
Linderolide U, a new sesquiterpene from Lindera aggregata root
Hye Jin Yang1, Eun Bin Kwon1, Wei Li1
1Korean Medicine (KM) Application Center, Korea Institute of Oriental Medicine, Daegu, Republic of Korea.
Natural Product Research
|September 14, 2020
Summary
Researchers isolated linderolide U from Lindera aggregata roots. Compound 5 demonstrated significant anticancer effects against colon cancer cells by inhibiting proliferation and inducing apoptosis.
Area of Science:
- Natural Product Chemistry
- Pharmacology
- Cancer Biology
Background:
- Lindera aggregata is a plant source of bioactive compounds.
- Sesquiterpenes are a class of natural products with diverse biological activities.
- Colon cancer remains a significant global health challenge.
Purpose of the Study:
- To isolate and characterize new and known sesquiterpenes from Lindera aggregata roots.
- To evaluate the in vitro anticancer effects of these isolated compounds against human colon cancer cells.
- To identify potential therapeutic agents for colon cancer treatment.
Main Methods:
- Isolation of compounds using chromatographic techniques.
- Structure elucidation by Nuclear Magnetic Resonance (NMR) spectroscopy and Mass Spectrometry (MS).
- Anticancer activity assessment using the HCT116 human colon cancer cell line, including proliferation assays, apoptosis detection, and cell cycle analysis.
Main Results:
- A new sesquiterpene, linderolide U (1), and five known sesquiterpenes (2-6) were isolated and identified.
- Compound 5 exhibited significant inhibition of HCT116 colon cancer cell proliferation.
- Compound 5 induced apoptosis and caused cell cycle arrest at the G2/M and S phases.
Conclusions:
- Linderolide U is a novel sesquiterpene isolated from Lindera aggregata.
- Compound 5 displays potent anticancer properties against colon cancer cells.
- Compound 5 shows promise as a potential therapeutic agent for colon cancer treatment.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.0K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.0K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.7K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.7K
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.3K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.3K
01:28Adrenergic Agonists: Mixed-Action Agents
1.2K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.2K